Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis.

Semeraro F, Colucci M, Caironi P, Masson S, Ammollo CT, Teli R, Semeraro N, Magnoli M, Salati G, Isetta M, Panigada M, Tonetti T, Tognoni G, Latini R, Pesenti A, Gattinoni L.

Crit Care Med. 2018 Mar;46(3):e221-e228. doi: 10.1097/CCM.0000000000002919.

PMID:
29261568
2.

Grape intake reduces thrombin generation and enhances plasma fibrinolysis. Potential role of circulating procoagulant microparticles.

Ammollo CT, Semeraro F, Milella RA, Antonacci D, Semeraro N, Colucci M.

J Nutr Biochem. 2017 Dec;50:66-73. doi: 10.1016/j.jnutbio.2017.08.012. Epub 2017 Sep 1.

PMID:
29040837
3.

Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.

Colucci M, Incampo F, Cannavò A, Menegatti M, Siboni SM, Zaccaria F, Semeraro N, Peyvandi F.

J Thromb Haemost. 2016 Aug;14(8):1603-14. doi: 10.1111/jth.13342. Epub 2016 Jul 18.

4.

Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.

Ammollo CT, Semeraro N, Carratù MR, Colucci M, Semeraro F.

J Pharmacol Exp Ther. 2016 Feb;356(2):305-13. doi: 10.1124/jpet.115.229823. Epub 2015 Nov 17.

5.

Coagulopathy of Acute Sepsis.

Semeraro N, Ammollo CT, Semeraro F, Colucci M.

Semin Thromb Hemost. 2015 Sep;41(6):650-8. doi: 10.1055/s-0035-1556730. Epub 2015 Aug 25. Review.

PMID:
26305237
6.

A modified prothrombin time to measure the anticoagulant activity of dabigatran.

Visino F, Zaccaria F, Semeraro N, Colucci M.

Thromb Res. 2014 Dec;134(6):1368-9. doi: 10.1016/j.thromres.2014.09.027. Epub 2014 Sep 28. No abstract available.

PMID:
25294590
7.

Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding.

Ammollo CT, Zaccaria F, Visino F, Testa S, Semeraro N, Colucci M.

Br J Haematol. 2015 Mar;168(6):911-3. doi: 10.1111/bjh.13168. Epub 2014 Oct 4. No abstract available.

PMID:
25283217
8.

The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.

Incampo F, Carrieri C, Semeraro N, Colucci M.

Thromb Res. 2014 Nov;134(5):1110-6. doi: 10.1016/j.thromres.2014.08.010. Epub 2014 Aug 23.

PMID:
25193406
9.

Co-administration of low molecular weight heparin enhances the profibrinolytic effect of warfarin through different mechanisms.

Incampo F, Carrieri C, Galasso R, Marino R, Ettorre CP, Semeraro N, Colucci M.

Thromb Res. 2014 Apr;133(4):634-9. doi: 10.1016/j.thromres.2013.12.035. Epub 2014 Jan 4.

PMID:
24438946
10.

Antithrombotic activity of 12 table grape varieties. Relationship with polyphenolic profile.

Carrieri C, Milella RA, Incampo F, Crupi P, Antonacci D, Semeraro N, Colucci M.

Food Chem. 2013 Oct 15;140(4):647-53. doi: 10.1016/j.foodchem.2012.10.132. Epub 2012 Nov 10.

PMID:
23692748
11.

Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.

Incampo F, Carrieri C, Galasso R, Scaraggi FA, Di Serio F, Woodhams B, Semeraro N, Colucci M.

J Thromb Haemost. 2013 Feb;11(2):315-24. doi: 10.1111/jth.12102.

12.

Skin extracts from 2 Italian table grapes (Italia and Palieri) inhibit tissue factor expression by human blood mononuclear cells.

Milella RA, Antonacci D, Crupi P, Incampo F, Carrieri C, Semeraro N, Colucci M.

J Food Sci. 2012 Aug;77(8):H154-9. doi: 10.1111/j.1750-3841.2012.02818.x.

PMID:
22860586
13.

Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1.

Semeraro F, Giordano P, Faienza MF, Cavallo L, Semeraro N, Colucci M.

Thromb Haemost. 2012 Aug;108(2):311-7. doi: 10.1160/TH11-12-0864. Epub 2012 Jun 28.

PMID:
22740053
14.

Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.

Colucci M, Semeraro N.

Thromb Res. 2012 Mar;129(3):314-9. doi: 10.1016/j.thromres.2011.10.031. Epub 2011 Nov 21. Review.

PMID:
22113149
15.

Sepsis, thrombosis and organ dysfunction.

Semeraro N, Ammollo CT, Semeraro F, Colucci M.

Thromb Res. 2012 Mar;129(3):290-5. doi: 10.1016/j.thromres.2011.10.013. Epub 2011 Nov 5. Review.

PMID:
22061311
16.

The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.

Carrieri C, Galasso R, Semeraro F, Ammollo CT, Semeraro N, Colucci M.

J Thromb Haemost. 2011 Jan;9(1):154-62. doi: 10.1111/j.1538-7836.2010.04120.x.

17.

Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses.

Paparella D, Semeraro F, Scrascia G, Galeone A, Ammollo CT, Kounakis G, de Luca Tupputi Schinosa L, Semeraro N, Colucci M.

Ann Thorac Surg. 2010 Feb;89(2):421-7. doi: 10.1016/j.athoracsur.2009.10.041.

PMID:
20103314
18.

Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.

Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M.

J Thromb Haemost. 2010 Apr;8(4):790-8. doi: 10.1111/j.1538-7836.2010.03739.x. Epub 2010 Jan 17.

19.

Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.

Semeraro N, Ammollo CT, Semeraro F, Colucci M.

Mediterr J Hematol Infect Dis. 2010 Aug 13;2(3):e2010024. doi: 10.4084/MJHID.2010.024.

20.

Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.

Semeraro F, Ammollo CT, Semeraro N, Colucci M.

Haematologica. 2009 Jun;94(6):819-26. doi: 10.3324/haematol.2008.000042. Epub 2009 Apr 18.

21.

The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.

Ammollo CT, Semeraro F, Semeraro N, Colucci M.

Thromb Haemost. 2009 Apr;101(4):782-5. No abstract available.

PMID:
19350129
22.

Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential.

Colucci M, Cattaneo M, Martinelli I, Semeraro F, Binetti BM, Semeraro N.

J Thromb Haemost. 2008 Sep;6(9):1571-7. doi: 10.1111/j.1538-7836.2008.03070.x. Epub 2008 Jul 4.

23.

Ochratoxin A inhibits the production of tissue factor and plasminogen activator inhibitor-2 by human blood mononuclear cells: another potential mechanism of immune-suppression.

Rossiello MR, Rotunno C, Coluccia A, Carratù MR, Di Santo A, Evangelista V, Semeraro N, Colucci M.

Toxicol Appl Pharmacol. 2008 Jun 1;229(2):227-31. doi: 10.1016/j.taap.2008.01.004. Epub 2008 Jan 26.

PMID:
18289624
24.

TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival.

Gresele P, Binetti BM, Branca G, Clerici C, Asciutti S, Morelli A, Semeraro N, Colucci M.

Thromb Res. 2008;121(6):763-8. Epub 2007 Oct 29.

PMID:
17915296
25.

Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence.

Altomare DF, Rotelli MT, Pentimone A, Rossiello MR, Martinelli E, Guglielmi A, De Fazio M, Marino F, Memeo V, Colucci M, Semeraro N.

Colorectal Dis. 2007 Feb;9(2):133-8.

PMID:
17223937
26.

Hyperprothrombinaemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis.

Binetti BM, Rotunno C, Tripodi A, Asti D, Semeraro F, Semeraro N, Colucci M.

Thromb Haemost. 2006 Apr;95(4):606-11.

PMID:
16601829
27.

A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression.

Rossiello MR, Momi S, Caracchini R, Giannini S, Guglielmini G, Monopoli A, Ongini E, Semeraro N, Colucci M, Gresele P.

J Thromb Haemost. 2005 Nov;3(11):2554-62.

28.

Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection.

Colucci M, Rossiello MR, Pentimone A, Berloco P, Russo F, Di Leo A, Semeraro N.

Thromb Res. 2005;116(6):471-7.

PMID:
16181982
29.

An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.

Colucci M, Simioni P, Piro D, Prandoni P, Pagnan A, Semeraro N.

Haematologica. 2003 Dec;88(12):1383-9.

30.

Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism.

Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N.

Blood. 2004 Mar 15;103(6):2157-61. Epub 2003 Nov 20.

31.

[Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma].

Altomare DF, Rotelli MT, Memeo V, Martinelli E, Guglielmi A, DeFazio M, D'Elia G, Pentimone A, Colucci M, Semeraro N.

Tumori. 2003 Jul-Aug;89(4 Suppl):5-6. Italian.

PMID:
12903530
32.

Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.

Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.

Hepatology. 2003 Jul;38(1):230-7.

PMID:
12830006
33.

Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.

Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D, Semeraro N.

Thromb Haemost. 2002 Aug;88(2):282-7.

PMID:
12195701
34.

Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.

Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N.

Thromb Haemost. 2001 Apr;85(4):661-6.

PMID:
11341502
35.

Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells.

Montemurro P, Barbuti G, Dundon WG, Del Giudice G, Rappuoli R, Colucci M, De Rinaldis P, Montecucco C, Semeraro N, Papini E.

J Infect Dis. 2001 Apr 1;183(7):1055-62. Epub 2001 Feb 23.

PMID:
11237830
36.

Monocytes, but not endothelial cells, downregulate the anticoagulant activity of activated protein C.

Colucci M, Stramaglia AM, Mascolo E, Napoleone E, Lorenzet R, Semeraro N.

Br J Haematol. 2001 Feb;112(2):519-26.

PMID:
11167857
37.

Platelets abolish the profibrinolytic effect of activated protein C.

Colucci M, Binetti BM, Semeraro N.

Thromb Haemost. 2000 Nov;84(5):922-3. No abstract available.

PMID:
11127881
38.

Fibrin down-regulates LPS- and PMA-induced tissue factor expression by blood mononuclear cells.

Rossiello MR, Italia A, Stramaglia AM, Gesualdo L, Grandaliano G, Schena FP, Semeraro N, Colucci M.

Thromb Haemost. 2000 Sep;84(3):453-9.

PMID:
11019971
39.

Retinoic acid stimulates plasminogen activator inhibitor 2 production by blood mononuclear cells and inhibits urokinase-induced extracellular proteolysis.

Montemurro P, Barbuti G, Conese M, Gabriele S, Petio M, Colucci M, Semeraro N.

Br J Haematol. 1999 Nov;107(2):294-9.

PMID:
10583214
40.

Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells.

Gesualdo L, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, Grandaliano G, Schena FP, Ursi M, Cerullo G.

Kidney Int. 1999 Aug;56(2):461-70.

41.

Prevention and therapy of experimental venous thrombosis in rabbits by desmin 370.

Colucci M, Rossiello MR, Barbanti M, Calanni F, Semeraro N.

Thromb Haemost. 1998 Aug;80(2):338-41.

PMID:
9716163
43.

Thrombolysis enhancing activity of a low molecular weight dermatan sulfate (Desmin 370) in experimental pulmonary embolism in rats.

Colucci M, Sardella L, Barbanti M, Calanni F, Semeraro N.

Thromb Res. 1997 Sep 1;87(5):441-6.

PMID:
9306618
44.

Tissue factor in health and disease.

Semeraro N, Colucci M.

Thromb Haemost. 1997 Jul;78(1):759-64. Review.

PMID:
9198252
45.
46.

Effect of Helicobacter pylori lipopolysaccharide (LPS) and LPS derivatives on the production of tissue factor and plasminogen activator inhibitor type 2 by human blood mononuclear cells.

Semeraro N, Montemurro P, Piccoli C, Muolo V, Colucci M, Giuliani G, Fumarola D, Pece S, Moran AP.

J Infect Dis. 1996 Dec;174(6):1255-60.

PMID:
8940216
47.

Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors.

Colucci M, Gesualdo L, Montemurro P, Cavallo LG, Conese M, Mascolo E, Ranieri E, Di Paolo S, Schena FP, Semeraro N.

Thromb Haemost. 1995 Dec;74(6):1516-20.

PMID:
8772230
48.

Desmin 370, a low molecular weight dermatan sulfate, reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod.

Barbanti M, Calanni F, Marchi E, Semeraro N, Colucci M.

Thromb Haemost. 1995 Feb;73(2):287-90.

PMID:
7792745
49.

Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.

Montemurro P, Conese M, Altomare DF, Memeo V, Colucci M, Semeraro N.

Int J Clin Lab Res. 1995;25(4):195-200.

PMID:
8788547
50.

Resistance to activated protein C (APC): influence of factor V levels.

Colucci M, Ciavarella N, Giliberti MG, Semeraro N.

Thromb Haemost. 1994 Dec;72(6):987-8. No abstract available.

PMID:
7740475

Supplemental Content

Loading ...
Support Center